ClinicalTrials.gg
Enrolling by invitationNCT06996925Updated Aug 12, 2025

Depression, Illness Perception, and Erectile Dysfunction Outcomes

An observational study in Erectile Dysfunction, Depression and Perception and Beliefs, sponsored by Haseki Training and Research Hospital. Enrolling by invitation at 1 site in Turkey (Türkiye). Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-12.

Sponsored by Haseki Training and Research Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Erectile Dysfunction with a site in Turkey — 6 open to participants now, 8 under way, 2 of them phase 3. Erectile Dysfunction · Turkey.

Planned enrollment
9th of 15
120 · median 130
Started
2025
with 5 others
Observational
15 of 32
1 open now
Registered
19th of 32
by date

Among the 32 studies in Erectile Dysfunction with a site in Turkey, this one is the 9th largest by planned enrollment of the 15 observational ones that give a count, is one of 6 that started in 2025, is one of 15 observational ones, and was the 19th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

6 of the 32 studies in Erectile Dysfunction with a site in Turkey are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Erectile Dysfunction with a site in Turkey, or all of them as a file.
02

Study summary

The goal of this observational study is to evaluate the impact of illness perception and depressive symptoms on treatment outcomes in adult male patients diagnosed with erectile dysfunction (ED).

The main questions it aims to answer are:

Is there a relationship between negative illness perception and increased severity of depressive symptoms in ED patients? Does the change in illness perception over time correlate with changes in erectile function and depression levels?

Participants will:

Complete the IIEF-5 (International Index of Erectile Function - 5) to assess erectile dysfunction severity, Complete the B-IPQ (Brief Illness Perception Questionnaire) to evaluate their cognitive and emotional representations of ED, Complete the PHQ-9 (Patient Health Questionnaire - 9) to measure depressive symptoms, Repeat these assessments at baseline and at a 1-month follow-up. This study does not involve any intervention or comparison group. It is designed to track psychological and clinical changes over time and explore modifiable psychological predictors in the management of ED.

Read the detailed description

This prospective, observational study aims to investigate the relationship between illness perception and depressive symptoms in patients diagnosed with erectile dysfunction (ED), and how these factors influence treatment response over time. Erectile dysfunction is a multifactorial condition that significantly affects quality of life and can be shaped by psychological and cognitive factors, including patients' perceptions of their disease.

A total of 120 adult male participants (aged >18 years) diagnosed with ED will be enrolled from multiple urology centers. Patients will complete three validated instruments at baseline and again at a 1-month follow-up:

IIEF-5 (International Index of Erectile Function - 5): to assess severity of erectile dysfunction.

B-IPQ (Brief Illness Perception Questionnaire): to evaluate cognitive and emotional representations of their condition.

PHQ-9 (Patient Health Questionnaire - 9): to screen for and quantify depressive symptoms.

The primary outcome of the study is to determine the association between baseline illness perception (as measured by B-IPQ) and the severity of depressive symptoms (PHQ-9 scores). Secondary outcomes include changes in erectile function (IIEF-5) and depressive symptoms at 1 month, and whether these changes correlate with changes in illness perception. Additionally, specific components of illness perception such as personal control, treatment control, concern, and emotional response will be analyzed in relation to treatment adherence and psychological well-being.

Data Quality and Management Procedures:

A structured case report form (CRF) will be used for consistent data entry. A data dictionary will define each variable and ensure uniform interpretation of collected data.

Data checks will be performed to validate internal consistency (e.g., checking for missing or out-of-range values).

Source data verification will involve comparison of collected responses with patients' medical records when applicable.

Standard Operating Procedures (SOPs) will be followed for data collection, participant follow-up, and data management.

Sample Size and Statistical Plan:

A power analysis indicated a required sample size of 120 participants to detect a moderate correlation (r = 0.3) between illness perception and depressive symptoms with 80% power and a 5% significance level.

Statistical analysis will include:

Descriptive statistics for demographic and clinical variables. Pearson or Spearman correlation analysis between B-IPQ, PHQ-9, and IIEF-5 scores.

Paired t-tests or Wilcoxon signed-rank tests to assess within-group changes over time.

Multivariate regression analysis to control for potential confounders such as age, comorbidities, and duration of ED.

Missing Data Plan:

Cases with missing responses will be addressed using multiple imputation methods where appropriate. Sensitivity analyses will be conducted to assess the impact of missing data on study outcomes.

This study will provide insight into how modifiable psychological factors such as illness beliefs influence both psychological distress and sexual health, potentially informing future patient education and intervention strategies.

03

Conditions studied

  • Erectile Dysfunction
  • Depression
  • Perception and Beliefs

Keywords

  • erectile dysfunction
  • Depression
  • self perception
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants will be recruited from the outpatient urology clinics of Haseki Training and Research Hospital and collaborating centers. All participants will be adult male patients who present with complaints consistent with erectile dysfunction and meet the diagnostic criteria during clinical evaluation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male patients aged 18 years or older
  • Diagnosed with erectile dysfunction by a physician
  • Able and willing to provide written

Exclusion criteria

Exclusion Criteria:

  • History of severe psychiatric disorders (e.g., schizophrenia, bipolar disorder)
  • Ongoing or prior hormonal therapy or active cancer treatment
  • Neurological conditions that could impact erectile function
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Target follow-up
1 Month
Patient registry
Yes

Groups and cohorts

  • Erectile Dysfunction

    This study includes adult male participants aged 18 and older who have been clinically diagnosed with erectile dysfunction (ED). All participants will have the condition of interest (ED), and there is no control group without the condition. The study group is homogeneous in that it consists solely of patients with ED, allowing for the evaluation of intra-individual changes over time in illness perception, depressive symptoms, and erectile functio

06

What researchers measure

Primary outcomes

  1. Association between illness perception and depressive symptoms

    Change in depressive symptom scores (Patient Health Questionnaire-9, PHQ-9; range 0-27; higher scores indicate worse depressive symptoms) in relation to illness perception scores (Brief Illness Perception Questionnaire, B-IPQ; range 0-80; higher scores indicate more negative illness perceptions) at baseline and 1-month follow-up.

    Time frame: Baseline and 1-month follow-up

07

Study locations

1 site
  • Haseki Education and Research Hospital
    Istanbul, Turkey (Türkiye)
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Individual participant data (IPD) will be made available to qualified researchers upon reasonable request. Requests will be evaluated by the principal investigator to ensure that the proposed use is scientifically and ethically appropriate. Data will be shared under a formal data use agreement that protects participant confidentiality and complies with ethical standards.

Supporting information: Study protocol, Informed consent form

Time frame: Data will be available starting 6 months after publication of the study results and will remain available for up to 2 years.

Access criteria: Qualified researchers affiliated with academic institutions, research organizations, or healthcare institutions may request access to the data. What information they can access: Individual participant data (IPD) Study protocol Statistical analysis plan Informed consent form (upon request) How they can access it: Researchers must submit a formal request to the principal investigator including a brief research proposal and institutional ethical approval. If the request is approved, a data use agreement (DUA) must be signed to ensure appropriate data handling and confidentiality. Access will then be granted through a secure, password-protected electronic transfer system managed by the study team.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Aug 2025, 5 months after the start.

Of 41 observational studies under Erectile Dysfunction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 77. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2025
First posted
May 30, 2025
StartActual
Mar 31, 2025
Primary completionEst.
Aug 31, 2025
CompletionEst.
Sep 30, 2025
Last update
Aug 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06996925
Lead sponsor
Haseki Training and Research Hospital
Responsible party
Nazım Furkan Günay (Urology specialist, Haseki Training and Research Hospital) — Principal investigator
First posted
May 30, 2025
Start date
Mar 31, 2025
Primary completion
Aug 31, 2025 (estimated)
Completion
Sep 30, 2025 (estimated)
Last update
Aug 12, 2025

Study contacts

Furkan Gunay, Medical doctor
principal investigator · Haseki Education and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion